TORONTO, ONTARIO, Sept. 10, 2026 (GLOBE NEWSWIRE) --

安大略省多伦多，2026年9月10日（环球社讯）--

COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“

COSCIENS Biopharma Inc.（多伦多证券交易所股票代码：CSCI）（OTCQB 市场股票代码：CSCIF）（“

COSCIENS

科希恩斯

” or the “

”或“

Company

公司

”) is pleased to announce the acquisition of Nualtis Corp. (“

）欣然宣布收购 Nualtis Corp.（“

Nualtis

努阿尔蒂斯

”), a Montreal-based specialty pharmaceutical technology business focused primarily on proprietary oral thin-film drug delivery technologies, with applications for both human and animal health. The Company also announced the completion of the first tranche of a non-brokered private placement of unsecured convertible debentures..

”），这是一家总部位于蒙特利尔的专业制药技术企业，主要专注于专有的口服薄膜给药技术，应用于人类和动物健康领域。该公司还宣布完成了无经纪人参与的非公开私募发行无担保可转换债券的第一批交易。

ACQUISITION HIGHLIGHTS:

收购亮点：

Strategic acquisition of a leading oral thin film (“OTF”) development and manufacturing platform:

战略收购领先的口服薄膜（“OTF”）开发和制造平台：

Nualtis is an industry leader and innovator in OTF drug delivery technology, adding a purpose-driven team and an FDA- and Health Canada-inspected GMP manufacturing facility in Montreal, Canada.

Nualtis 是口腔薄膜（OTF）给药技术领域的行业领导者和创新者，拥有一支以使命为驱动的团队，并在加拿大蒙特利尔设有一家通过美国食品药品监督管理局（FDA）和加拿大卫生部检查的药品生产质量管理规范（GMP）制造设施。

Established development and commercial partnerships across a diversified product pipeline:

在多元化的产品管线中建立了开发和商业合作伙伴关系：

A portfolio of programs spanning human and animal health, protected by 21 foundational patents, with partnerships in place with established pharmaceutical companies.

一个涵盖人类和动物健康的项目组合，受21项基础专利保护，并与知名制药公司建立了合作关系。

Growing cash-flow-positive business model:

现金流为正的商业模式不断增长：

The Company believes Nualtis is poised for continued, profitable future growth through diverse revenue streams, including research and development (“

本公司认为，Nualtis 已准备好通过包括研发在内的多元化收入来源，实现持续且盈利的未来增长。

R&D

研发

”) services, manufacturing and supply, milestone payments, and product royalties.

”）服务、制造与供应、里程碑付款以及产品特许权使用费。

“We are very excited to announce the acquisition of Nualtis. COSCIENS now has direct exposure to the large and growing global OTF market through Nualtis’ leading facility, intellectual property and know-how, and its established product pipeline and partnerships,” said Peter Puccetti, CEO and Chairman of COSCIENS.

“我们非常激动地宣布收购Nualtis。通过Nualtis的领先设施、知识产权与专有技术，以及其成熟的产品管线和合作伙伴关系，COSCIENS现在能够直接涉足庞大且不断增长的全球OTF市场。”COSCIENS首席执行官兼董事长Peter Puccetti表示。

“Since joining COSCIENS last year, I, and my fellow directors and officers, have been committed to a plan for creating shareholder value. During an initial period of restructuring, we made significant improvements in the Company’s financial health and on achieving financial self-sufficiency of the existing business.

“自去年加入COSCIENS以来，我与各位董事及高级管理人员一直致力于实施一项创造股东价值的计划。在初步重组阶段，我们显著改善了公司的财务状况，并推动了现有业务实现财务自给自足。”

In Q2, Ceapro contributed over US$422,000 of income from operations and we believe it will continue to meaningfully contribute to earnings going forward. More recently, we shifted our focus to actively exploring opportunities for growth and scale. We believe this transaction represents exactly that.

在第二季度，Ceapro 贡献了超过 42.2 万美元的营业利润，我们相信它未来将继续对盈利做出重大贡献。最近，我们将重心转向积极寻求增长和规模扩张的机会。我们认为此次交易正契合这一战略方向。

Nualtis is led by a talented and driven management team and is positioned for significant growth as it transitions from mostly R&D revenue to more commercial-scale manufacturing revenue. We believe that COSCIENS is well-positioned to help guide and support that growth path.”.

Nualtis 由一支才华横溢且充满进取心的管理团队领导，随着公司从主要依赖研发收入转向更具商业规模的制造收入，已为实现显著增长做好定位。我们相信，COSCIENS 具备良好优势，能够引导并支持这一增长路径。

Michael Raven, CEO of Nualtis since 2024, commented “We have made great improvements to Nualtis’ business strategy and approach over the last couple of years laying the seeds for substantial profitable growth. COSCIENS’ ownership will provide Nualtis with a platform from which to continue what it has started and Nualtis management couldn’t be more excited about the future of the business.”.

自2024年起担任Nualtis首席执行官的Michael Raven表示：“在过去几年中，我们对Nualtis的业务战略和方法进行了重大改进，为实质性的盈利增长奠定了基础。COSCIENS的控股将为Nualtis提供一个平台，使其能够延续已启动的发展势头，Nualtis管理层对公司未来的发展前景感到无比振奋。”

The Acquisition and the Acquired Business

收购方与被收购业务

The acquisition was completed pursuant to a share purchase agreement between the Company and AtaiBeckley Inc. (“

该收购已根据本公司与AtaiBeckley Inc.（“

AtaiBeckley

阿泰·贝克利

”) for a cash purchase price of US$15 million, subject to customary adjustments, plus up to four earn-out payments based on a formula specified in the purchase agreement and equal to 10% of the EBITDA of Nualtis (adjusted in accordance with the purchase agreement) for the financial years 2027 through 2030 (subject to certain other adjustments specified in the purchase agreement).

”）以1,500万美元的现金购买价格进行收购，须按惯例进行调整，此外还包括最多四笔基于购买协议中规定的公式计算的盈利支付款项，金额等于Nualtis公司在2027至2030财年期间经调整（按照购买协议规定）的息税折旧摊销前利润（EBITDA）的10%（须受购买协议中规定的其他特定调整约束）。

At closing, the Company made an initial payment of US$9 million (the “.

在交割时，公司支付了首付款900万美元（“

Closing Date Purchase Price

交割日期 购买价格

”), subject to adjustments, and the remaining US$6 million is due as a deferred payment within six months (the “

”），须作调整，剩余600万美元作为延期付款在六个月内到期（“

Deferred Payment

延期付款

”).

”）。

Nualtis (formerly IntelGenx Corp.) was established in 2003. It specializes in the development of oral thin film technology and operates as a contract development and manufacturing organization. The global pharmaceutical oral thin film market was estimated at US$3.8 billion in 2024 and is expected to grow significantly over the next few years..

Nualtis（前身为IntelGenx Corp.）成立于2003年，专注于口服薄膜技术的开发，并以合同研发与制造组织的模式运营。2024年，全球制药口服薄膜市场规模估计为38亿美元，预计在未来几年将显著增长。

1

1

In addition, Nualtis offers a broad portfolio of pharmaceutical services, including pharmaceutical R&D, clinical monitoring, regulatory support, analytical testing, licensing, and commercial manufacturing. Nualtis also holds a Health Canada Drug Establishment Licence, in respect of importation, manufacturing, packaging, labeling, and testing.

此外，Nualtis 提供广泛的制药服务组合，包括药物研发、临床监查、法规支持、分析测试、许可授权以及商业化生产。Nualtis 还持有加拿大卫生部颁发的药品机构许可证，涵盖进口、生产、包装、标签和测试等业务。

Nualtis typically applies its oral thin film platforms to active pharmaceutical ingredients with a known mechanism of action and an established safety profile, which keeps development timelines and costs low and gives partners a faster and lower-risk path to differentiated products..

Nualtis 通常将其口服薄膜平台应用于具有已知作用机制和既定安全性特征的活性药物成分，从而缩短开发周期并降低成本，为合作伙伴提供一条更快速、更低风险的差异化产品开发路径。

Nualtis’ product development is anchored by two proprietary oral thin film platforms: VersaFilm

Nualtis 的产品开发以两大专有口服薄膜平台为基石：VersaFilm

®

注册商标符号

for human therapeutics and VetaFilm

用于人类治疗药物和VetaFilm

®

®

for veterinary applications. Both use a thin, FDA-compliant polymeric film that dissolves quickly in the mouth, offering an alternative to traditional tablets.

用于兽医应用。两者均采用一种符合FDA标准的薄型聚合物薄膜，可在口腔中迅速溶解，为传统片剂提供了一种替代方案。

Nualtis’ product pipeline is well-diversified, spanning a mix of generic, branded, over-the-counter (“

Nualtis的产品管线多元化程度高，涵盖仿制药、品牌药和非处方药（“

OTC

场外交易

”) and prescription products, in various therapeutic areas and with multiple partners. The product pipeline also represents various stages of product development, spanning from early-stage R&D to products expected to reach commercial launch in the near term. Within the next five years, the Company believes the successful commercialization of products in Nualtis’ existing pipeline could result in tens of millions of dollars in annual revenue..

”）以及处方药产品，涵盖多个治疗领域，并与多家合作伙伴共同推进。产品管线也代表了产品开发的各个阶段，从早期研发到预计近期可实现商业上市的产品。在未来五年内，公司认为，Nualtis现有管线中产品的成功商业化可能带来数千万美元的年收入。

Set out below is some additional detail on certain programs within the portfolio representing exemplary near- and medium-term opportunities:

下文列出了投资组合中某些项目的更多细节，这些项目代表了近期和中期的典范机会：

Human Health / Migraine

人类健康 / 偏头痛

RizaFilm

里扎电影

®

®

(a registered trademark of Nualtis’ partner, Gensco Laboratories LLC (“

（Nualtis 合作伙伴 Gensco Laboratories LLC 的注册商标（“

Gensco

Gensco

”)) is a proprietary prescription oral thin film containing rizatriptan benzoate. RizaFilm is the first and only FDA-approved oral dissolvable film for migraine in the United States, approved for adults (10 mg) in April 2023 and for pediatric patients (5 mg) in February 2026. Gensco Pharma owns the global rights and has announced a U.S.

”)) 是一种含有苯甲酸利扎曲坦的专有处方口服薄膜。RizaFilm 是美国首个且唯一获美国食品药品监督管理局（FDA）批准的用于偏头痛治疗的口服速溶薄膜，于2023年4月获批用于成人（10 mg），并于2026年2月获批用于儿科患者（5 mg）。Gensco Pharma 拥有其全球权利，并已宣布在美国

launch in October 2026, with Nualtis as its manufacturer..

于2026年10月发布，制造商为Nualtis。

The film is placed on the tongue and dissolves rapidly without a drink, allowing patients to treat at the earliest onset of symptoms, and is protected by an issued patent with substantial remaining exclusivity.

该药膜置于舌上后可迅速溶解，无需饮水，使患者能够在症状初现时即刻进行治疗，并受已授权专利保护，享有可观的剩余独占期。

Migraine affects more than 42 million Americans and is the second leading cause of disability nationwide.

偏头痛影响着超过4200万美国人，是全国范围内致残的第二大原因。

2

2

The global migraine drugs market was approximately US$7.9 billion in 2025 and is projected to reach US$16.6 billion by 2033 (9.2% CAGR).

2025年全球偏头痛药物市场规模约为79亿美元，预计到2033年将达到166亿美元（复合年增长率为9.2%）。

3

3

Human Health / Chronic Pain

人类健康 / 慢性疼痛

Nualtis and Chemo Research, S.L., together with its affiliate Xiromed LLC (collectively, “

Nualtis and Chemo Research, S.L. 及其关联公司 Xiromed LLC（统称为“

Xiromed

西罗梅德

”), are developing a generic buprenorphine buccal film that incorporates Nualtis’ VersaFilm

”），正在开发一种采用 Nualtis 公司 VersaFilm 技术的通用型丁丙诺啡颊膜

®

®

technology and is intended to be a generic version of Belbuca

技术，旨在作为 Belbuca 的通用版本

®

注册商标符号

, an opioid delivered as a buccal film and indicated for severe chronic pain. Nualtis is responsible for product development and manufacturing-related activities, while Xiromed is responsible for the regulatory approval and commercialization of the product.

，一种以口腔黏膜薄膜形式给药的阿片类药物，适用于治疗严重慢性疼痛。Nualtis 负责产品开发及与生产相关的活动，而 Xiromed 则负责该产品的监管审批和商业化。

Net revenue of Belbuca

Belbuca 的净收入

®

®

was $221.7 million for FY2025, up 5% year-over-year

2025财年为2.217亿美元，同比增长5%

4

4

in the U.S. market. No generic versions of Belbuca

在美国市场。Belbuca 没有仿制药版本

®

®

have been launched to date in the United States.

迄今为止在美国已推出。

Animal Health

动物健康

In collaboration with Covenant Animal Health Partners (“

与圣约动物健康合作伙伴（“

Covenant

盟约

”), Nualtis has developed an undisclosed, proprietary formulation for a veterinary use case in a market that has seen greater than US$100 million in annual sales. Initial clinical studies have shown positive results and received positive feedback from veterinarians.

），Nualtis 已开发出一种未公开的专有配方，用于一个年销售额超过1亿美元的兽医市场应用场景。初步临床研究显示出积极结果，并获得了兽医的正面反馈。

We look forward to providing further updates regarding the product pipeline and as programs and candidates advance through development, regulatory approval and commercialization.

我们期待随着产品管线中的项目和候选药物在研发、监管审批及商业化进程中不断取得进展，提供进一步的更新信息。

The Concurrent Financing

并发融资

To finance the Closing Date Purchase Price, the Company completed the first tranche of a concurrent non-brokered private placement (the “

为支付交割日购买价款，公司完成了同步进行的非经纪私募配售的第一批次（“

Offering

产品

”) of unsecured convertible debentures (the “

”）的无担保可转换债券（“

Debentures

债券

”) in an aggregate principal amount of approximately US$6 million. The terms of the Debentures contemplate the issuance of an aggregate principal amount of up to US$20 million, and the Company anticipates closing one or more additional tranches in the coming weeks. Additional subscriptions have already been received by the Company for more than US$4 million and the Company expects to receive further subscriptions in time for an anticipated second tranche closing next week..

本金总额约为600万美元。该等债券的条款设想发行本金总额高达2,000万美元，公司预计在未来几周内完成一笔或多笔额外批次的交割。公司已收到超过400万美元的额外认购，并预计在下周预期的第二批次交割前进一步收到认购。

“Between COSCIENS’ existing cash resources and the proceeds of the first tranche of Debentures, COSCIENS continues to have excess cash after payment of the Closing Date Purchase Price and accounting for all related payments and transaction expenses. Additional closings of the Debentures for a total of US$20 million would also leave COSCIENS with a material excess cash balance after the second payment to AtaiBeckley in approximately 6 months’ time,” said Giuliano La Fratta, CFO of COSCIENS..

“凭借COSCIENS现有的现金资源以及第一批债券发行的收益，在支付交割日购买价款并计入所有相关付款和交易费用后，COSCIENS仍拥有充裕的现金余额。”COSCIENS首席财务官Giuliano La Fratta表示，“若债券额外完成总计2,000万美元的后续交割，则在约6个月后向AtaiBeckley进行第二笔付款后，COSCIENS仍将保有重大的超额现金余额。”

Completion of additional tranches is subject to customary closing conditions, and there can be no assurance that additional tranches will be completed for the anticipated amount or at all.

完成额外批次交易须满足惯常的交割条件，且无法保证额外批次交易将按预期金额完成或最终能够完成。

The Debentures bear an annual interest of 15.0%, payable monthly in arrears, and mature on September 10, 2027 (the “

该债券年利率为15.0%，按月后付，于2027年9月10日到期（“

Maturity Date

到期日

”), and in certain circumstances and subject to shareholder approval, are convertible into common shares of the Company (“

”），并且在某些情况下，须经股东批准，可转换为本公司的普通股（“

Common Shares

普通股

”) at a price of US$7.00 per Common Share, subject to adjustment (the “

”）以每股普通股7.00美元的价格，可予调整（“

Conversion Price

转换价格

”). The Conversion Price is subject to customary anti-dilution provisions and an additional downward adjustment (the “

”）。转换价格受惯常的反稀释条款及额外的向下调整（“

Ratchet

棘轮

”) if the Company completes an equity raise prior to the Maturity Date at an issue price per Common Share that is less than the Conversion Price.

”）如果公司在到期日之前完成股权融资，且每股普通股的发行价格低于转换价格。

Pursuant to the rules and policies of the Toronto Stock Exchange (the “

根据多伦多证券交易所（“

TSX

多伦多证券交易所

”), the conversion rights and certain related terms (including the Ratchet) require shareholder approval. Notably, Section 611 of the TSX Company Manual generally requires shareholder approval where the common shares issuable in payment of the purchase price for an acquisition (including in a concurrent private placement upon which the acquisition is contingent or otherwise linked) exceeds 25% of the number of common shares that are outstanding, on a non-diluted basis.

”），转换权及某些相关条款（包括反稀释调整机制）需要获得股东批准。值得注意的是，《多伦多证券交易所公司手册》第611节通常规定，如果为支付收购对价而发行的普通股（包括在以此收购为前提条件或以其他方式与之关联的同步私募配售中发行的股份）超过已发行普通股数量（按非稀释基础计算）的25%，则需获得股东批准。

As of September 10, 2026, there were 997,219 outstanding Common Shares. If the Debentures issued in today’s closing were converted in full at the Conversion Price, it would result in the issuance of approximately 850,000 additional Common Shares (or approximately 85% of the currently outstanding Common Shares).

截至2026年9月10日，已发行在外的普通股数量为997,219股。如果今日收盘时发行的可转换债券全部按转换价格进行转换，将导致额外发行约850,000股普通股（约占当前已发行在外普通股的85%）。

The Company has agreed to call a meeting of shareholders (the “.

本公司已同意召开股东会议（“

Meeting

会议

”) within six months to seek the necessary approvals. Additional details will be provided in a forthcoming management information circular, which, once filed, will be available on SEDAR+ at

”）在六个月内寻求必要的批准。更多详情将在 forthcoming 的管理信息通告中提供，该通告一旦提交，即可在 SEDAR+ 上查阅，网址为

www.sedarplus.ca

www.sedarplus.ca

.

。

If all necessary shareholder and TSX approvals (the “

如果获得所有必要的股东批准和TSX批准（“

Required Approvals

所需审批

”) are obtained, the Company may, in its sole discretion, require the conversion of all or any portion of the aggregate principal amount of Debentures into Common Shares at the Conversion Price. The Company’s conversion right is not conditional on the Common Shares trading above a specified market price or satisfying a minimum trading-volume or liquidity threshold..

”）时，公司可自行决定要求将债券的全部或部分本金总额按转换价格转换为普通股。公司的转换权不以普通股交易价格高于特定市场价格或满足最低交易量或流动性门槛为条件。

Following the Meeting, whether or not the Required Approvals are obtained, the Company will have a right at any time to repay all or any portion of the Debentures in cash, at par, provided that, if the Company seeks to repay the Debentures in cash (whether as an early repayment or at Maturity), each of the holder of Debentures will, subject to receipt of the Required Approvals, first have the option to convert at the Conversion Price.

会议结束后，无论是否获得所需批准，公司均有权随时以面值现金偿还全部或部分债券；但前提是，若公司寻求以现金偿还债券（无论是提前偿还还是到期偿还），在获得所需批准的前提下，每位债券持有人应首先享有按转换价格进行转换的选择权。

Interest will, in all cases, be paid in cash..

在所有情况下，利息将以现金支付。

Certain directors and officers (the “

某些董事和高级管理人员（“

related parties

关联方

”) of the Company are participating in the Offering for an aggregate principal amount of approximately US$1.3 million, and accordingly the Offering is a “related party transaction” within the meaning of Multilateral Instrument 61-101 -

）的本公司正参与本次发行，总本金金额约为130万美元，因此本次发行构成《多边文书61-101》意义上的“关联方交易”。

Protection of Minority Security Holders in Special Transactions

特殊交易中对少数证券持有人的保护

(“

（“

MI 61-101

MI 61-101

”). Additional demand from insiders of the Company could not be met, as the Company is relying on the exemptions from the formal valuation and minority shareholder approval requirements of MI 61-101 contained in sections 5.5(a) and 5.7(1)(a) of MI 61-101, on the basis that at the time the Offering was agreed to, neither the fair market value of the Debentures nor the consideration paid therefor, insofar as it involved the related parties, exceeds 25% of the Company’s market capitalization (as determined as at the end of August in accordance with MI 61-101).

”）。由于公司依赖于《多边工具 61-101》（MI 61-101）第 5.5(a) 条和第 5.7(1)(a) 条所载的豁免，免于遵守该工具中关于正式估值及少数股东批准的要求，因此无法满足公司内部人士的额外需求。该豁免的依据是，在同意本次发售时，债券的公平市场价值以及就此支付的对价（在涉及关联方的范围内）均未超过公司市值的 25%（根据公司多边工具 61-101 的规定，以八月底的数据为准）。

Additional details will be provided in a forthcoming material change report, which, once filed, will be available on SEDAR+ at www.sedarplus.ca..

更多详情将在即将发布的重大变更报告中提供，该报告在提交后，可在 SEDAR+ 网站（www.sedarplus.ca）上查阅。

In connection with this closing, the Company agreed to pay finders’ fees (a “

就此次交割而言，公司同意支付中介费（“

Finder’s Fee

介绍费

”) on certain subscriptions, which Finder’s Fees may be satisfied in cash or through the issuance of Debentures. Total Finder’s Fees for the closing amounted to US$181,250 aggregate principal amount of Debentures. Any Debentures issued as Finder’s Fees will be counted towards the maximum aggregate principal amount of US$20,000,000..

”）针对某些认购，介绍费可以现金或发行债权证的方式支付。就本次交割而言，介绍费总额为本金总额181,250美元的债权证。任何作为介绍费发行的债权证均将计入20,000,000美元的最高本金总额上限。

The Debentures (and Common Shares issuable upon conversion of the Debentures) are subject to a four-month hold period under Canadian securities laws.

根据加拿大证券法，该等债券（以及可因转换该等债券而发行的普通股）须遵守四个月的禁售期。

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described in this news release in the United States. Such securities have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “

本新闻稿不构成在美国出售或征求购买本新闻稿所述任何证券的要约。此类证券未曾且将不会根据经修订的《1933年美国证券法》（“

U.S. Securities Act

美国证券法

”), or any state securities laws, and, accordingly, may not be offered or sold within the United States, or to or for the account or benefit of persons in the United States or “U.S. Persons”, as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S.

”），或任何州证券法，因此，除非根据美国法律注册，否则不得在美国境内向任何人或为任何人的账户或利益要约或出售，也不得向“美国人”（该术语定义见根据美国《证券法》颁布的S条例）或为其账户或利益要约或出售。

Securities Act and applicable state securities laws or pursuant to an exemption from such registration requirements..

证券法及适用的州证券法，或根据此类注册要求的豁免规定。

About COSCIENS Biopharma Inc.

关于COSCIENS生物制药公司

COSCIENS Biopharma Inc. is a holding company operating through its subsidiaries, including Ceapro Inc. (“

COSCIENS Biopharma Inc. 是一家控股公司，通过其子公司（包括 Ceapro Inc.（“

Ceapro

西普罗

”) and Nualtis

”）和努阿尔提斯

TM

商标

.

。

Ceapro is focused on the development and commercialization of natural, plant-based active ingredients derived from oats and other renewable plant resources, using proprietary manufacturing and extraction technologies. Ceapro’s primary active ingredient business activities relate to the development and commercialization of natural products for the personal care, cosmetic, human and animal health industries..

Ceapro 专注于利用专有制造和提取技术，开发和商业化源自燕麦及其他可再生植物资源的天然植物基活性成分。Ceapro 的核心活性成分业务活动涉及为个人护理、化妆品、人类健康及动物健康行业开发和商业化天然产品。

Nualtis is a specialty pharmaceutical technology business focused primarily on proprietary oral thin-film drug delivery technologies. Its business model includes pharmaceutical formulation development, analytical and regulatory support services, contract development and manufacturing activities, partner-sponsored development programs and commercial product manufacturing..

Nualtis 是一家专业制药技术企业，主要专注于专有的口服薄膜给药技术。其商业模式包括药物制剂开发、分析与监管支持服务、合同开发与生产活动、合作伙伴资助的开发项目以及商业化产品生产。

The Company’s common shares are listed on the TSX under the symbol “CSCI” and are listed and posted for trading on the OTCQB

该公司的普通股在多伦多证券交易所（TSX）上市，股票代码为“CSCI”，并在OTCQB市场上市并挂牌交易。

®

®

Venture Market under the symbol “CSCIF”. For more information, please visit COSCIENS’ website at www.cosciensbio.com.

创业市场，股票代码为“CSCIF”。欲了解更多信息，请访问 COSCIENS 官方网站 www.cosciensbio.com。

Forward-Looking Statements

前瞻性陈述

Certain statements in this news release constitute “forward-looking statements” and/or “forward-looking information” under applicable securities laws. All statements, other than statements of historical fact, that address circumstances, events, activities, or developments that could or may or will occur are forward-looking statements.

本新闻稿中的某些陈述根据适用的证券法律构成“前瞻性陈述”和/或“前瞻性信息”。除历史事实陈述外，所有涉及可能、或许或将会发生的情形、事件、活动或发展的陈述均为前瞻性陈述。

When used in this news release, words such as “anticipate”, “assume”, “believe”, “could”, “expect”, “forecast”, “future”, “goal”, “guidance”, “intend”, “likely”, “may”, “would” or the negative or comparable terminology as well as terms usually used in the future and the conditional are generally intended to identify forward-looking statements, although not all forward-looking statements include such words.

在本新闻稿中，诸如“预期”、“假设”、“相信”、“可能”、“预计”、“预测”、“未来”、“目标”、“指引”、“打算”、“大概”、“可以”、“将会”等词语，或其否定形式或类似表述，以及通常用于将来时和条件时的术语，一般旨在标识前瞻性陈述，尽管并非所有前瞻性陈述都包含此类词语。

Specific forward-looking statements in this document include, but are not limited to, statements relating to: the expected benefits of the Nualtis acquisition; the timing and outcome of regulatory submissions, approvals and related commercialization activities for Nualtis’ product pipeline; the growth of the markets in which Nualtis’ product pipeline operates; manufacturing validation, scale-up and commercialization readiness for Nualtis’ product pipeline; the anticipated revenue and other potential economic contributions associated with Nualtis’ product pipeline; the timing, number and nature of expected commercial product launches from Nualtis’ product pipeline; the development, regulatory pathway, commercialization and market opportunity for Nualtis’ human and animal health programs; the expectation of and timing to complete additional tranches of the Offering; the conversion, repayment and potential dilution associated with the Debentures; the timing to hold the Meeting to receive the Required Approvals; the Company’s ability to fund.

本文件中的具体前瞻性陈述包括但不限于以下方面的陈述：Nualtis 收购的预期收益；Nualtis 产品管线的监管申报、审批及相关商业化活动的时间安排和结果；Nualtis 产品管线所在市场的增长；Nualtis 产品管线的生产验证、规模放大及商业化准备情况；与 Nualtis 产品管线相关的预期收入及其他潜在经济贡献；Nualtis 产品管线预期的商业产品发布的时间、数量及性质；Nualtis 人用和动物健康项目的开发、监管路径、商业化及市场机会；完成额外批次发行的预期及时间安排；与债券相关的转换、偿还及潜在稀释效应；召开会议以获取必要批准的时间安排；公司的资金筹措能力。

The forward-looking statements and financial outlook information contained in this news release are based on a number of material factors, expectations, assumptions and estimates made by the Company in light of its experience and perception of historical trends, current conditions and expected future developments, including, without limitation, assumptions regarding: the successful integration of Nualtis into the Company’s operations; the ability of Nualtis and its partners to continue to perform their respective contractual obligations and maintain existing commercial relationships; the continued validity, enforceability and availability of applicable intellectual property rights; the ability of Nualtis and its partners to successfully complete development activities, clinical studies, analytical work, manufacturing validation and scale-up activities within anticipated timelines; the ability of Nualtis to find commercial partners for products in its pipeline; the timely submission, review and receipt of required regulatory approvals; the absence of material adverse regulatory findings, manufacturing deficiencies, safety concerns, intellectual property disputes or litigation outcomes (including ongoing patent litigation relating to Belbuca.

本新闻稿中包含的前瞻性陈述和财务展望信息基于公司根据其经验以及对历史趋势、当前状况和预期未来发展的理解所作出的多项重要因素、预期、假设和估计，包括但不限于以下假设：成功将Nualtis整合到公司的运营中；Nualtis及其合作伙伴能够继续履行各自的合同义务并维持现有的商业关系；适用的知识产权权利持续有效、可执行且可用；Nualtis及其合作伙伴能够在预期的时间框架内成功完成开发活动、临床研究、分析工作、生产验证和规模化活动；Nualtis能够为其产品管线中的产品找到商业合作伙伴；及时提交、审查并获得所需的监管批准；不存在重大的不利监管发现、生产缺陷、安全问题、知识产权纠纷或诉讼结果（包括与Belbuca相关的正在进行的专利诉讼）。

®

®

) that would materially delay or prevent commercialization; the ability of Nualtis’ partners to successfully commercialize, market and distribute products incorporating Nualtis’ technology; expected market acceptance of such products; contractual economics under existing and future partner arrangements being in line with expectations; the availability of sufficient manufacturing capacity; the absence of material launch delays or partner non-performance; the capacity of Nualtis’ partners to fund, market, distribute and commercialize applicable products as expected; the ability of the Company to complete additional tranches of the Offering and otherwise satisfy the Deferred Payment and other funding requirements; the availability of capital on acceptable terms; prevailing economic, market, industry and regulatory conditions; and the continued execution of the Company’s strategic plans..

）可能导致商业化重大延迟或受阻的因素；Nualtis 的合作伙伴成功将采用 Nualtis 技术的产品商业化、营销和分销的能力；市场对此类产品的预期接受度；现有及未来合作伙伴协议下的合同经济性与预期一致；充足的制造产能的可获得性；不存在重大的发布延迟或合作伙伴未履行义务的情况；Nualtis 的合作伙伴按预期为相关产品提供资金、营销、分销和商业化的能力；公司完成额外批次发行并 otherwise 满足递延付款及其他融资要求的能力；以可接受条款获得资本的可获得性；当前的经济、市场、行业和监管条件；以及公司持续执行其战略计划。

Actual results may differ materially from those expressed or implied by the forward-looking statements contained herein. Factors that could cause actual results to differ materially include, without limitation: risks associated with the integration of Nualtis; failure to realize anticipated benefits of the acquisition; delays in, or failure to obtain, required regulatory approvals; unsuccessful clinical, development or validation activities; manufacturing, scale-up or supply-chain challenges or the inability to finance any required capex expenditures; the inability of Nualtis or its partners to successfully commercialize products or achieve anticipated market acceptance; adverse intellectual property developments, including litigation outcomes; the failure of current or future partners to perform as expected; delays in, or failure to achieve, anticipated product launches; the inability to enter into, maintain or expand partner or commercialization arrangements on acceptable terms or at all; changes in market conditions, competitive dynamics, pricing, reimbursement or customer demand; the inability to complete additional tranches of the Offering or otherwise obtain sufficient financing; the inability to satisfy the Deferred Payment when due; dilution resulting from the Debentures; general economic, geopolitical, market or industry conditions; and the other risk factors described in the Company’s public disclosure documents filed on SEDAR+..

实际结果可能与本文所载前瞻性陈述中明示或暗示的结果存在重大差异。可能导致实际结果出现重大差异的因素包括但不限于：与Nualtis整合相关的风险；未能实现收购的预期效益；在获得必要的监管批准方面出现延误或未能获得批准；临床试验、开发或验证活动未获成功；制造、规模化生产或供应链方面的挑战，或无法为任何所需的资本支出提供资金；Nualtis及其合作伙伴未能成功将产品商业化或实现预期的市场接受度；不利的知识产权发展，包括诉讼结果；现有或未来合作伙伴未能按预期履行义务；预期产品发布出现延误或未能实现；无法以可接受的条款（或根本无法）订立、维持或扩展合作伙伴关系或商业化安排；市场状况、竞争格局、定价、报销政策或客户需求的变化；无法完成发行的额外批次或以其他方式获得充足的融资；无法在到期时支付递延付款；因债券发行导致的股权稀释；总体经济、地缘政治、市场或行业状况；以及公司在SEDAR+上提交的公开披露文件中所述的其他风险因素。

Certain forward-looking statements contained herein, including estimates regarding anticipated revenue, commercialization timing and potential economic contribution of products in the Nualtis pipeline, may constitute a “financial outlook” within the meaning of applicable securities laws. Such financial outlook is based on the assumptions described above, together with assumptions regarding launch timing, manufacturing capacity, anticipated production volumes, partner commercialization activities, market penetration, pricing, royalty rates and other contractual economics.

本文包含的某些前瞻性陈述，包括对Nualtis管线中产品的预期收入、商业化时机及潜在经济贡献的估计，可能构成适用证券法意义上的“财务展望”。此类财务展望基于上述假设，以及关于上市时机、生产能力、预期产量、合作伙伴商业化活动、市场渗透率、定价、特许权使用费率和其他合同经济性因素的假设。

The financial outlook is provided solely to assist readers in evaluating the potential contribution of the applicable product to Nualtis’ business if commercialization occurs and may not be appropriate for any other purpose. There can be no assurance that the assumptions underlying such financial outlook will prove correct, and actual results may differ materially from those reflected therein.

提供财务展望仅旨在协助读者评估在实现商业化的情况下，适用产品对Nualtis业务的潜在贡献，且可能不适用于任何其他目的。无法保证此类财务展望所依据的假设将被证实为正确，实际结果可能与其中反映的结果存在重大差异。

Readers are cautioned that such financial outlook information contained herein should not be used for purposes other than for which it is disclosed..

提醒读者，此处包含的财务展望信息仅可用于其披露的目的，不得用于其他用途。

No securities regulatory authority has either approved or disapproved of the contents of this news release. The Toronto Stock Exchange accepts no responsibility for the adequacy or accuracy of this news release.

任何证券监管机构均未对本新闻稿的内容表示批准或不批准。多伦多证券交易所不对本新闻稿的充分性或准确性承担任何责任。

Issuer Contact:

发行人联系方式：

Peter H. Puccetti

彼得·H·普切蒂

Chief Executive Officer and Chairman of the Board

首席执行官兼董事会主席

ppuccetti@cosciensbio.com

ppuccetti@cosciensbio.com

Giuliano La Fratta

朱利亚诺·拉弗拉塔

Chief Financial Officer

首席财务官

glafratta@cosciensbio.com

glafratta@cosciensbio.com

Investor Contact:

投资者联系：

IR@cosciensbio.com

IR@cosciensbio.com

1

1

Source: Skyquest Technology. https://www.skyquestt.com/report/oral-thin-films-market.

来源：Skyquest Technology。https://www.skyquestt.com/report/oral-thin-films-market。

2

2

Source: American Migraine Foundation. Migraine and Headache Awareness Month 2025. https://americanmigrainefoundation.org/migraine-and-headache-awareness-month-2/

来源：美国偏头痛基金会。2025年偏头痛与头痛意识月。https://americanmigrainefoundation.org/migraine-and-headache-awareness-month-2/

3

3

Source: Grand View Research. Migraine Drugs Market (2026 – 2033). https://www.grandviewresearch.com/industry-analysis/migraine-drugs-market

来源：Grand View Research。偏头痛药物市场（2026–2033年）。https://www.grandviewresearch.com/industry-analysis/migraine-drugs-market

4

4

Source: Collegium Pharmaceutical, Inc Corporate press release, [Feb. 26, 2026].

来源：Collegium Pharmaceutical, Inc. 企业新闻稿，[2026年2月26日]。